M P Yavropoulou1, N A T Hamdy, S E Papapoulos. 1. Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Abstract
UNLABELLED: We addressed the question whether the response of osteoporotic patients to bisphosphonate treatment is reduced with time. Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate. Response of osteoporotic patients to bisphosphonates is not impaired during their long-term administration. INTRODUCTION: Inadequate response to bisphosphonate treatment has been described in patients with Paget's disease of bone but has not been addressed in osteoporosis although treatment failure is a clinically relevant problem. METHODS: Twenty one women with postmenopausal osteoporosis (PMO) aged 68 ± 8.2 years and 14 women with glucocorticoid-induced osteoporosis (GIOP) aged 65 ± 10 years were treated with tri-monthly intravenous infusions of 45 mg of pamidronate for 1 year. All patients had been previously treated with bisphosphonates (alendronate, risedronate, pamidronate) for a mean period of 6.2 years (range, 1.3-14 years). Blood samples were taken for measurement of the bone resorption marker C-terminal crosslinking telopeptide of type I collagen (CTX-I) on days 1 and 4 and of the bone formation marker procollagen type I N propeptide, (P1NP) on day 1 of every tri-monthly treatment course. RESULTS: With each treatment course there was a significant decrease in serum CTX-I on day 4 and an increase to baseline values 3 months after each infusion in both PMO (mean values, day 1: 291.33 ± 160.78 pg/ml vs. day 4: 131 ± 91.7 pg/ml, p < 0.001) and GIOP (day 1: 219.3 ± 114.8 pg/ml vs. day 4: 98.8 ± 51.6 pg/ml, p < 0.001). Serum P1NP remained stable during the whole year of treatment. CONCLUSIONS: Long-term bisphosphonate treatment of women with either PMO or GIOP does not impair the response to subsequently administered intravenous pamidronate suggesting that inadequate response to long-term bisphosphonate treatment is not responsible for treatment failure.
UNLABELLED: We addressed the question whether the response of osteoporoticpatients to bisphosphonate treatment is reduced with time. Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate. Response of osteoporoticpatients to bisphosphonates is not impaired during their long-term administration. INTRODUCTION: Inadequate response to bisphosphonate treatment has been described in patients with Paget's disease of bone but has not been addressed in osteoporosis although treatment failure is a clinically relevant problem. METHODS: Twenty one women with postmenopausal osteoporosis (PMO) aged 68 ± 8.2 years and 14 women with glucocorticoid-induced osteoporosis (GIOP) aged 65 ± 10 years were treated with tri-monthly intravenous infusions of 45 mg of pamidronate for 1 year. All patients had been previously treated with bisphosphonates (alendronate, risedronate, pamidronate) for a mean period of 6.2 years (range, 1.3-14 years). Blood samples were taken for measurement of the bone resorption marker C-terminal crosslinking telopeptide of type I collagen (CTX-I) on days 1 and 4 and of the bone formation marker procollagen type I N propeptide, (P1NP) on day 1 of every tri-monthly treatment course. RESULTS: With each treatment course there was a significant decrease in serum CTX-I on day 4 and an increase to baseline values 3 months after each infusion in both PMO (mean values, day 1: 291.33 ± 160.78 pg/ml vs. day 4: 131 ± 91.7 pg/ml, p < 0.001) and GIOP (day 1: 219.3 ± 114.8 pg/ml vs. day 4: 98.8 ± 51.6 pg/ml, p < 0.001). Serum P1NP remained stable during the whole year of treatment. CONCLUSIONS: Long-term bisphosphonate treatment of women with either PMO or GIOP does not impair the response to subsequently administered intravenous pamidronate suggesting that inadequate response to long-term bisphosphonate treatment is not responsible for treatment failure.
Authors: Adolfo Díez-Pérez; Jose M Olmos; Xavier Nogués; Manuel Sosa; Manuel Díaz-Curiel; Jose Luis Pérez-Castrillón; Ramon Pérez-Cano; Manuel Muñoz-Torres; Antonio Torrijos; Esteban Jodar; Luis Del Rio; Jose R Caeiro-Rey; Jordi Farrerons; Joan Vila; Claude Arnaud; Jesus González-Macías Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: P D Miller; R R Recker; J-Y Reginster; B J Riis; E Czerwinski; D Masanauskaite; A Kenwright; R Lorenc; J A Stakkestad; P Lakatos Journal: Osteoporos Int Date: 2011-09-28 Impact factor: 4.507
Authors: Ma Victoria Hernández; Pilar Peris; Ana Monegal; Raquel Reyes; Africa Muxi; Laia Gifre; Nuria Guañabens Journal: Am J Med Sci Date: 2010-03 Impact factor: 2.378
Authors: D H Gutteridge; L C Ward; G O Stewart; R W Retallack; R K Will; R L Prince; A Criddle; C I Bhagat; B G Stuckey; R I Price; G N Kent; D L Faulkner; E Geelhoed; S K Gan; S Vasikaran Journal: J Bone Miner Res Date: 1999-10 Impact factor: 6.741
Authors: E Cauza; M Etemad; F Winkler; U Hanusch-Enserer; H Hanusch-Enserer; G Partsch; H Noske; A Dunky Journal: J Clin Pharm Ther Date: 2004-10 Impact factor: 2.512
Authors: A Diez-Perez; J D Adachi; D Agnusdei; J P Bilezikian; J E Compston; S R Cummings; R Eastell; E F Eriksen; J Gonzalez-Macias; U A Liberman; D A Wahl; E Seeman; J A Kanis; C Cooper Journal: Osteoporos Int Date: 2012-07-27 Impact factor: 4.507
Authors: Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741